Physician

John Michael Hemphill, M.D.

According to 2025 Medicare claims, John Hemphill, M.D. (NPI: 1285672329) practices neurology in the Savannah, GA market, with the plurality of this provider's patient population coming from Chatham, GA. This provider's primary affiliated billing organization is SAVANNAH NEUROLOGY SPECIALISTS P C (NPI: 1629203294; TIN: 264598467) and primary practice location at 31406-2778.

Hemphill's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 695 traditional Medicare patients, billed 180,251 HCPCS/CPT codes, and received $1,378,253 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 5,734 prescription claims across 714 beneficiaries totaling $4,357,263 in drug costs, led by Mavenclad (Cladribine). 2023 DME data shows 12 claims. Open Payments data shows 649 records totaling $839,985. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $514,808 to $1,378,253. Similarly, Part D prescription costs have risen steadily, from $2,243,973 to $4,357,263. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $26,964 to $596.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	608	52,199	$514,808
2016	627	45,728	$467,599
2017	689	72,810	$1,098,826
2018	737	64,898	$1,181,651
2019	703	67,580	$1,391,591
2020	826	57,104	$1,095,298
2021	811	66,847	$969,422
2022	700	85,483	$1,319,458
2023	711	89,278	$1,185,299
2024	695	180,251	$1,378,253

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	314	3,646	$2,243,973
2016	341	3,987	$3,343,723
2017	347	4,060	$3,385,318
2018	401	3,907	$3,165,317
2019	478	4,785	$3,974,904
2020	561	5,144	$4,288,495
2021	713	5,760	$5,330,836
2022	763	6,306	$5,561,987
2023	711	5,913	$5,709,908
2024	714	5,734	$4,357,263

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$2,601
2016	N/R	22	$1,140
2017	N/R	12	$465
2018	N/R	15	$1,183
2019	N/R	N/R	N/R
2020	N/R	12	$120
2021	N/R	16	$722
2022	N/R	12	$615
2023	N/R	12	$334
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	105	105	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	303	428	$79
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	215	287	$57
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	113	399	$44
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	494	822	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Mavenclad	Cladribine	11	648	$692,095
Vumerity	Diroximel Fumarate	72	2,220	$639,876
Gammaplex	Immun Glob G(Igg)/Gly/Iga 0-50	17	511	$452,064
Austedo	Deutetrabenazine	21	630	$209,451
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	23	644	$164,716

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	539	$385,224	Eisai Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	110	$454,761	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John Michael Hemphill, M.D.?

Tedicare shows public-source Medicare data for John Michael Hemphill, M.D. (NPI 1285672329), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John Michael Hemphill, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John Michael Hemphill, M.D.?

John Michael Hemphill, M.D. is linked to SAVANNAH NEUROLOGY SPECIALISTS P C (billing NPI 1629203294) in the available physician profile data.

Does John Michael Hemphill, M.D. have Open Payments data?

John Michael Hemphill, M.D. has 649 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.